For instance, while CD133 has been used as a marker to identify CSCs in glioblastoma [22] and CRC [23], it is not a reliable marker in breast cancer where CD44+CD24− is commonly used to enrich for CSCs [24]. The gene discussed is PROM1; the disease is colorectal carcinoma.